Dr. Reddy's Laboratories Limited
DRREDDY
Rangering i aksjer
#1915
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's... Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsible for the production and distribution of prescription and over-the-counter finished pharmaceutical products, marketed either under their own brand names or as generic versions therapeutically equivalent to branded formulations, also encompassing biologics. The Pharmaceutical Services and Active Ingredients (PSAI) division manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates, which are fundamental components for finished drugs, alongside offering contract research services and custom production of APIs and steroids. The Proprietary Products segment is dedicated to the research and development of unique and differentiated drug formulations. Furthermore, its "Others" segment focuses on developing treatments for oncology and inflammatory conditions. The company's therapeutic reach spans numerous areas including gastro-intestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatological, urological, and nephrological health. Dr. Reddy's also maintains a strategic collaboration with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists for immuno-oncology and precision oncology applications.
Aksjekurs
$13.01
Markedsverdi
$10.84B
Endring (1 dag)
-4.88%
Endring (1 år)
-11.14%
Land
IN
Handel Dr. Reddy's Laboratories Limited (DRREDDY)
Kategori
Healthcare
P/E-forhold for Dr. Reddy's Laboratories Limited (DRREDDY)
P/E-forhold per 2026 TTM: 0
Ifølge Dr. Reddy's Laboratories Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Dr. Reddy's Laboratories Limited fra 2026 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | - |
IN
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.